529 related articles for article (PubMed ID: 10521756)
21. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
22. Urine tests for Down's syndrome screening.
Alldred SK; Guo B; Takwoingi Y; Pennant M; Wisniewski S; Deeks JJ; Neilson JP; Alfirevic Z
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011984. PubMed ID: 26662198
[TBL] [Abstract][Full Text] [Related]
23. Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment.
Cole LA; Rinne KM; Mahajan SM; Oz UA; Shahabi S; Mahoney MJ; Bahado-Singh RO
Prenat Diagn; 1999 Apr; 19(4):340-50. PubMed ID: 10327140
[TBL] [Abstract][Full Text] [Related]
24. Alpha-fetoprotein, free beta-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome.
Wenstrom KD; Owen J; Chu DC; Boots L
Am J Obstet Gynecol; 1997 Nov; 177(5):987-91. PubMed ID: 9396880
[TBL] [Abstract][Full Text] [Related]
25. Second-trimester maternal serum screening for Down's syndrome: free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol.
Extermann P; Bischof P; Marguerat P; Mermillod B
Hum Reprod; 1998 Jan; 13(1):220-3. PubMed ID: 9512261
[TBL] [Abstract][Full Text] [Related]
26. Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies.
Cole LA; Acuna E; Isozaki T; Palomaki GE; Bahado-Singh RO; Mahoney MO
Prenat Diagn; 1997 Dec; 17(12):1125-33. PubMed ID: 9467809
[TBL] [Abstract][Full Text] [Related]
27. Screening of maternal serum for fetal Down's syndrome in the first trimester.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
29. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
30. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
31. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
32. The advantages of using triple-marker screening for chromosomal abnormalities.
Kellner LH; Weiss RR; Weiner Z; Neuer M; Martin GM; Schulman H; Lipper S
Am J Obstet Gynecol; 1995 Mar; 172(3):831-6. PubMed ID: 7534448
[TBL] [Abstract][Full Text] [Related]
33. Maternal serum screening for alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities.
Crandall BF; Hanson FW; Keener S; Matsumoto M; Miller W
Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 1):1864-7; discussion 1867-9. PubMed ID: 7686337
[TBL] [Abstract][Full Text] [Related]
34. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
[TBL] [Abstract][Full Text] [Related]
35. Second trimester maternal serum screening using alpha fetoprotein, free beta human chorionic gonadotropin and maternal age specific risk: result of chromosomal abnormalities detected in screen positive for Down syndrome in an Asian population.
Chao AS; Chung CL; Wu CD; Chang SD; Cheng PJ; Lin YT; Soong YK
Acta Obstet Gynecol Scand; 1999 May; 78(5):393-7. PubMed ID: 10326883
[TBL] [Abstract][Full Text] [Related]
36. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
37. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
Dick PT
CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
[TBL] [Abstract][Full Text] [Related]
38. The triple-marker test in predicting fetal aneuploidy: a compromise between sensitivity and specificity.
Huderer-Duric K; Skrablin S; Kuvacic I; Sonicki Z; Rubala D; Suchanek E
Eur J Obstet Gynecol Reprod Biol; 2000 Jan; 88(1):49-55. PubMed ID: 10659916
[TBL] [Abstract][Full Text] [Related]
39. Practical strategies in contingent sequential screening for Down syndrome.
Benn P; Wright D; Cuckle H
Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
[TBL] [Abstract][Full Text] [Related]
40. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
Benn PA; Ying J; Beazoglou T; Egan JF
Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
